# PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

> **NCT01521494** · PHASE2 · COMPLETED · sponsor: **Kissei Pharmaceutical Co., Ltd.** · enrollment: 183 (actual)

## Conditions studied

- Chronic Kidney Disease Requiring Hemodialysis

## Interventions

- **DRUG:** PA21
- **DRUG:** PA21
- **DRUG:** PA21
- **DRUG:** PA21
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01521494
- **Lead sponsor:** Kissei Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-11
- **Primary completion:** 2012-07-03
- **Final completion:** 2012-07-03
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2018-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01521494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01521494, "PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01521494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*